Recent Advances in Drug Development and Regulatory Science in China-Reference-Cited by-同舟云学术

Recent Advances in Drug Development and Regulatory Science in China

Published:2018-11 Issue:6 Volume:52 Page:739-750
ISSN:2168-4790
Container-title:Therapeutic Innovation & Regulatory Science
language:en
Short-container-title:Ther Innov Regul Sci

Author:

Chen Jie^ORCID,Zhao Naiqing

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Public Health, Environmental and Occupational Health,Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Link

http://link.springer.com/content/pdf/10.1177/2168479018764661.pdf

Reference32 articles.

1. International Trade Administration: 2016 top markets report pharmaceuticals country case study—china. Technical report, 2017, U.S. Department of Commerce.

2. GlobalData. Country focus: healthcare, regulatory and reimbursement landscape. US. Technical Report, 2016, GlobalData UK Ltd.

3. IMS: IMS Market Prognosis 2016-2020 Asia/Australia China. Technical report, 2016, IMS Health, London.

4. United Nations. World Population Ageing 2015. Department of Economics and Social Affairs, 2015, United Nations, New York.

5. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. Cancer J Clin. 2016;66:115–132.

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pathway to Approval of Innovative Radiopharmaceuticals in China;Journal of Nuclear Medicine;2024-05

2. Scientometrics Evaluation of Published Scientific Papers on the Use of Proteomics Technologies in Mastitis Research in Ruminants;Pathogens;2024-04-15

3. A call to rethink the necessity of and challenges facing academic research organizations in the new era of drug innovation in China;Drug Discovery Today;2024-04

4. Trends, lag and characteristics of orphan drug approvals in the USA and China, 1983-2022;2023-12-02

5. The reimbursement decision speed for oncology new drugs in China and its determinant factors;Frontiers in Public Health;2023-10-30